Keros Therapeutics, Inc. is a pharmaceutical company in the United States dedicated to advancing innovative treatments for hematological, pulmonary, and cardiovascular disorders. Their focus on ESG principles drives their mission to address unmet medical needs. With a Medium Risk ESG score of 28.0, Keros Therapeutics is committed to developing protein therapeutic products like KER-050 for conditions such as anemia and thrombocytopenia in patients with MDS and myelofibrosis.